BrainTest SEZC Can Identify and Detect Early Signs of Mild Cognitive Impairment

George Town, Grand Cayman, Cayman Islands (4 March 2022) – A new study published in Alzheimer’s Research & Therapy finds that self-administered test, the Self-Administered Gerocognitive Examination (SAGE test), developed by researchers at The Ohio State University Wexner Medical Center, College of Medicine and College of Public Health can identify the early, subtle signs of Mild Cognitive Impairment (MCI), a condition if treated early can delay the onset of dementia and Alzheimer’s disease, sooner than the most commonly used office-based standard cognitive tests.

 The BrainTest® app, created by Cayman Islands MedTech company, BrainTest SEZC, is the digital version of SAGE, which is a new at-home screening test.

The Cayman Enterprise City (CEC) Special Economic Zone Company (SEZC) led by Michael Kader, President of BrainTest SEZC, has been a part of the CEC community since 2016. “We are extremely pleased to offer BrainTest as a resource that will empower consumers to take charge of their brain health, especially as new therapeutics for dementia and Alzheimer’s disease are being developed and approved,” said Kader.

The medical software company, headquartered in the Cayman Islands, provides a scientifically validated cognitive screening instrument on a wide range of tablets and mobile devices. The company empowers patients, around the globe, to monitor their cognition and learn objective evidence-based recommendations about their brain health in the comfort and privacy of their own homes. Through its partnership with The Ohio State University, BrainTest SEZC holds the exclusive digital rights to the Self-Administered Gerocognitive Examination (SAGE Test).

BrainTest® can be taken anywhere whenever there are cognitive concerns, and it only takes about 10-15 minutes to complete. The cognitive domains tested include orientation, language, calculations, memory, abstraction, executive function, and constructional abilities. Results can be taken to primary care physicians, who can decide if any additional steps are needed. This digital version developed by BrainTest SEZC will also be integrated with the Ohio State Wexner Medical Center’s electronic medical records system to better facilitate self-testing, storing, and reviewing results by their health care providers.

Even though SAGE and BrainTest® may be taken at home, only BrainTest® can be scored remotely as part of the service model. The BrainTest® core scoring lab can turn the results around quickly, providing a printable detailed report with a video explanation by a certified physician. Those results can be taken to their primary care physician, who can decide if any additional steps are needed. SAGE users will need to bring the test to a physician, for scoring. Consumers may start with one free BrainTest®, plus a 30-day free access to the application to try. 

More than 6 million Americans have Alzheimer’s disease, and those numbers are expected to rise to more than 13 million by 2050. Deaths from Alzheimer’s and other dementias have increased 16% during the COVID-19 pandemic, according to the Alzheimer’s Association.

“Cayman Enterprise City has been developed to attract new knowledge-based industries to the Cayman Islands, diversify Cayman’s economy, and provide a global platform for innovation,” said Charlie Kirkconnell, Chief Executive Officer at CEC. “It’s exciting to see globally significant projects, like BrainTest SEZC, that are innovating within the global MedTech sector, developing new technology, and making a significant impact, right here from the Cayman Islands. Congratulations to Michael Kader and the BrainTest SEZC team for releasing the first digital, scientifically proven, self-administered Alzheimer's test.”

Learn more about BrainTest® at https://braintest.com/ and learn more about CEC at https://www.caymanenterprisecity.com/.